Abstract
Systemic autoimmune disease in humans and mice is characterized by loss of immunologic tolerance to a restricted set of self-nuclear antigens. Autoantigens, such as double-stranded (ds) DNA and the RNA-containing Smith antigen (Sm), may be selectively targeted in systemic lupus erythematosus because of their ability to activate a putative common receptor. Toll-like receptor 9 (TLR9), a receptor for CpG DNA, has been implicated in the activation of autoreactive B cells in vitro, but its role in promoting autoantibody production and disease in vivo has not been determined. We show that in TLR9-deficient lupus-prone mice, the generation of anti-dsDNA and antichromatin autoantibodies is specifically inhibited. Other autoantibodies, such as anti-Sm, are maintained and even increased in TLR9-deficient mice. In contrast, ablation of TLR3, a receptor for dsRNA, did not inhibit the formation of autoantibodies to either RNA- or DNA-containing antigens. Surprisingly, we found that despite the lack of anti-dsDNA autoantibodies in TLR9-deficient mice, there was no effect on the development of clinical autoimmune disease or nephritis. These results demonstrate a specific requirement for TLR9 in autoantibody formation in vivo and indicate a critical role for innate immune activation in autoimmunity.
References
68
Referenced
436
10.7326/0003-4819-83-4-464
/ Ann. Intern. Med. (1975)10.1016/S0092-8674(00)81108-3
/ Cell. (1996)10.1038/nri976
/ Nat. Rev. Immunol. (2003)10.1016/S0889-857X(21)00735-3
/ Rheum. Dis. Clin. North Am. (1992)10.1056/NEJM199805073381906
/ N. Engl. J. Med. (1998)10.1136/jcp.53.6.424
/ J. Clin. Pathol. (2000)10.1146/annurev.immunol.21.120601.141126
/ Annu. Rev. Immunol. (2003)10.1038/ni1112
/ Nat. Immunol. (2004)10.1038/35047123
/ Nature. (2000)10.1182/blood-2002-11-3569
/ Blood. (2003)10.1038/416603a
/ Nature. (2002)10.1016/S1074-7613(03)00323-6
/ Immunity. (2003)10.1177/09680519040100040801
/ J. Endotoxin Res. (2004)10.1038/35099560
/ Nature. (2001)10.1074/jbc.M310175200
/ J. Biol. Chem. (2004)10.1016/S0955-0674(00)00211-8
/ Curr. Opin. Cell Biol. (2001)10.1146/annurev.iy.09.040191.001331
/ Annu. Rev. Immunol. (1991)10.4049/jimmunol.133.1.227
/ J. Immunol. (1984)10.1084/jem.180.4.1295
/ J. Exp. Med. (1994)10.4049/jimmunol.157.1.417
/ J. Immunol. (1996)10.1002/art.1780251101
/ Arthritis Rheum. (1982)10.1002/art.1780400910
/ Arthritis Rheum. (1997){'key': '2023072513185829200_BIB23'}
10.1111/j.1749-6632.1975.tb29197.x
/ Ann. NY Acad. Sci. (1975)10.1136/ard.46.6.448
/ Ann. Rheum. Dis. (1987)10.5858/2000-124-0071-GFCUOT
/ Arch. Pathol. Lab. Med. (2000)10.1016/S0021-9258(18)91101-4
/ J. Biol. Chem. (1984)10.4049/jimmunol.150.4.1591
/ J. Immunol. (1993)10.1073/pnas.241510698
/ Proc. Natl. Acad. Sci. USA. (2001)10.1056/NEJMoa021933
/ N. Engl. J. Med. (2003)10.1016/S0896-8411(02)00114-2
/ J. Autoimmun. (2003)10.1038/35100573
/ Nat. Rev. Immunol. (2001)10.1073/pnas.0337679100
/ Proc. Natl. Acad. Sci. USA. (2003)10.1084/jem.20021553
/ J. Exp. Med. (2003)10.4049/jimmunol.173.8.5283
/ J. Immunol. (2004)10.1084/jem.20021996
/ J. Exp. Med. (2003)10.4049/jimmunol.173.3.2134
/ J. Immunol. (2004)10.1084/jem.20030162
/ J. Exp. Med. (2003)10.1126/science.1087262
/ Science. (2003)10.1093/intimm/11.10.1693
/ Int. Immunol. (1999)10.1093/intimm/dxg020
/ Int. Immunol. (2003)10.4049/jimmunol.167.5.2602
/ J. Immunol. (2001)10.1084/jem.20031942
/ J. Exp. Med. (2004)10.1038/ni1028
/ Nat. Immunol. (2004)10.1084/jem.179.4.1317
/ J. Exp. Med. (1994)10.1101/gad.1022802
/ Genes Dev. (2002)10.1038/ni1146
/ Nat. Immunol. (2005)10.1084/jem.20012094
/ J. Exp. Med. (2002)10.1146/annurev.immunol.22.012703.104549
/ Annu. Rev. Immunol. (2004)10.1093/intimm/dxf046
/ Int. Immunol. (2002)10.4049/jimmunol.164.11.5998
/ J. Immunol. (2000)10.4049/jimmunol.168.9.4531
/ J. Immunol. (2002)10.1126/science.1093616
/ Science. (2004)10.1126/science.1093620
/ Science. (2004)10.1038/nature01783
/ Nature. (2003)10.1038/ni1010
/ Nat. Immunol. (2003)10.1038/nature03124
/ Nature. (2004)10.1084/jem.20030130
/ J. Exp. Med. (2003)10.1002/art.1780371118
/ Arthritis Rheum. (1994)10.1038/ki.1992.242
/ Kidney Int. (1992)10.1136/ard.62.6.556
/ Ann. Rheum. Dis. (2003)10.1084/jem.20031519
/ J. Exp. Med. (2004)10.1084/jem.189.10.1639
/ J. Exp. Med. (1999)10.1016/S1074-7613(01)00251-5
/ Immunity. (2001)10.1016/j.cell.2004.07.002
/ Cell. (2004)10.1073/pnas.97.3.1184
/ Proc. Natl. Acad. Sci. USA. (2000)10.1002/eji.1830131107
/ Eur. J. Immunol. (1983)10.1126/science.7025211
/ Science. (1981)
Dates
Type | When |
---|---|
Created | 20 years, 1 month ago (July 18, 2005, 3:03 p.m.) |
Deposited | 2 years, 1 month ago (July 25, 2023, 9:21 a.m.) |
Indexed | 3 days, 1 hour ago (Sept. 3, 2025, 6:15 a.m.) |
Issued | 20 years, 1 month ago (July 18, 2005) |
Published | 20 years, 1 month ago (July 18, 2005) |
Published Online | 20 years, 1 month ago (July 18, 2005) |
Published Print | 20 years, 1 month ago (July 18, 2005) |
@article{Christensen_2005, title={Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus}, volume={202}, ISSN={0022-1007}, url={http://dx.doi.org/10.1084/jem.20050338}, DOI={10.1084/jem.20050338}, number={2}, journal={The Journal of Experimental Medicine}, publisher={Rockefeller University Press}, author={Christensen, Sean R. and Kashgarian, Michael and Alexopoulou, Lena and Flavell, Richard A. and Akira, Shizuo and Shlomchik, Mark J.}, year={2005}, month=jul, pages={321–331} }